0001179110-13-006722.txt : 20130411
0001179110-13-006722.hdr.sgml : 20130411
20130411214502
ACCESSION NUMBER: 0001179110-13-006722
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130410
FILED AS OF DATE: 20130411
DATE AS OF CHANGE: 20130411
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WOOD JULIANNA R
CENTRAL INDEX KEY: 0001282660
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28298
FILM NUMBER: 13757364
MAIL ADDRESS:
STREET 1: 3031 RESEARCH DR
STREET 2: BLDG A
CITY: RICHMOND
STATE: CA
ZIP: 84806
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001012140
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943154463
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 249 E. GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-266-0000
MAIL ADDRESS:
STREET 1: 249 E. GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
edgar.xml
FORM 4 -
X0306
4
2013-04-10
0
0001012140
ONYX PHARMACEUTICALS INC
ONXX
0001282660
WOOD JULIANNA R
C/O ONYX PHARMACEUTICALS, INC.
249 E. GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
VP, Public Affairs
Common Stock
2013-04-10
4
M
0
547
35.18
A
19921
D
Common Stock
2013-04-10
4
M
0
220
28.55
A
20141
D
Common Stock
2013-04-10
4
M
0
1198
37.68
A
21339
D
Common Stock
2013-04-10
4
M
0
619
30.28
A
21958
D
Common Stock
2013-04-10
4
M
0
600
28.55
A
22558
D
Common Stock
2013-04-10
4
M
0
146
30.28
A
22704
D
Common Stock
2013-04-10
4
S
0
3330
95.0032
D
19374
D
Common Stock
2013-04-10
4
M
0
510
30.28
A
19884
D
Common Stock
2013-04-10
4
M
0
440
28.55
A
20324
D
Common Stock
2013-04-10
4
M
0
1437
37.68
A
21761
D
Common Stock
2013-04-10
4
M
0
3645
35.18
A
25406
D
Common Stock
2013-04-10
4
M
0
586
28.55
A
25992
D
Common Stock
2013-04-10
4
S
0
6618
95.00
D
19374
D
Common Stock
200
I
Children's Trust
Stock Option (Right to Buy)
35.18
2013-04-10
4
M
0
547
0.00
D
2021-03-31
Common Stock
547
12760
D
Stock Option (Right to Buy)
35.18
2013-04-10
4
M
0
3645
0.00
D
2021-03-31
Common Stock
3645
9115
D
Stock Option (Right to Buy)
28.55
2013-04-10
4
M
0
220
0.00
D
2019-03-31
Common Stock
220
2173
D
Stock Option (Right to Buy)
28.55
2013-04-10
4
M
0
600
0.00
D
2019-03-31
Common Stock
600
1573
D
Stock Option (Right to Buy)
28.55
2013-04-10
4
M
0
440
0.00
D
2019-03-31
Common Stock
440
1133
D
Stock Option (Right to Buy)
28.55
2013-04-10
4
M
0
586
0.00
D
2019-03-31
Common Stock
586
547
D
Stock Option (Right to Buy)
37.68
2013-04-10
4
M
0
1198
0.00
D
2022-03-29
Common Stock
1198
19166
D
Stock Option (Right to Buy)
37.68
2013-04-10
4
M
0
1437
0.00
D
2022-03-29
Common Stock
1437
17729
D
Stock Option (Right to Buy)
30.28
2013-04-10
4
M
0
619
0.00
D
2020-03-31
Common Stock
619
7291
D
Stock Option (Right to Buy)
30.28
2013-04-10
4
M
0
146
0.00
D
2020-03-31
Common Stock
146
7145
D
Stock Option (Right to Buy)
30.28
2013-04-10
4
M
0
510
0.00
D
2020-03-31
Common Stock
510
6635
D
Shares sold pursuant to a 10b5-1 plan.
The shares were sold at prices ranging from $95.00 to $95.08. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
/s/ Warren DeSouza, Attorney-In-Fact
2013-04-11